[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sle-systemic-lupus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sle-systemic-lupus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,61,85,111,139,163,187,210,230,255],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100587219","phase-1-a-safety-and-efficacy-study-evaluating-ctx112-in-adult-subjects-with-refractory-autoimmune-disease-100587219",false,"NCT06925542","A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease","A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease","Key Inclusion Criteria:\n\n1. Age ≥18 years and \\\u003C 70 years of age.\n2. Subjects must voluntarily sign a written informed consent and be willing and able to comply with all study requirements.\n3. Adequate hematologic, renal, liver, cardiac and pulmonary organ function.\n4. Subjects must agree to use acceptable methods of contraception.\n5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other study procedures.\n6. Diagnosis of systemic lupus erythematosus (SLE), systemic sclerosis (SSc) or idiopathic inflammatory myopathy (IIM).\n\nFor systemic lupus erythematosus (SLE) subjects:\n\n\\- Diagnosis of SLE by a board-certified rheumatologist that conforms with 2019 ACR\u002FEULAR criteria. For lupus nephritis subjects, active, biopsy-proven proliferative lupus nephritis Class III or IV, either with or without the presence of Class V, and appropriate National Institutes of Health index activity score using the 2018 International Society of Nephrology\u002FRenal Pathology Society criteria.\n\nFor Systemic Sclerosis (SSc) subjects:\n\n\\- Diagnosis of diffuse cutaneous systemic sclerosis (dcSSC) or SSc-ILD that conforms with 2013 ACR\u002FEULAR criteria. Subjects should meet active skin or lung disease criteria.\n\nFor Idiopathic Inflammatory Myopathy (IIM) subjects:\n\n\\- Diagnosis with dermatomyositis (DM), polymyositis (PM) or myositis as part of rheumatologic overlap syndrome, antisynthetase (ASyS), or immune-mediated necrotizing myopathy (IMNM) that conforms with 2017 ACR\u002FEULAR criteria for inflammatory myopathies. Subjects must meet moderate severe, skin, or lung involvement criteria.\n\nKey Exclusion Criteria:\n\n1. Prior anti-CD19 therapy or any gene therapy\u002Fgenetically modified cell therapy.\n2. Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.\n3. Severe active or history of central nervous (CNS) involvement.\n4. History of a seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease or any autoimmune disease with CNS involvement other than SLE, SSc or IIM.\n5. Mixed connective tissue disease with no clear predominant disease.\n6. Presence of study disease manifestations or other conditions that are likely to pose increase safety risks and\u002For confound disease assessments, or pose significant risk to those receiving CAR T cell therapy.\n7. History of primary or secondary immunodeficiency.\n8. Presence or history of certain bacterial, viral or fungal infection.\n9. Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence).\n10. Diagnosis of a genetic disorder associated with bone marrow failure or myelodysplastic syndrome.\n11. History or current diagnosis of catastrophic anti-phospholipid syndrome or anti phospholipid syndrome that requires ongoing anticoagulation.\n12. Pregnant or lactating.\n13. Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.","ALL","18 Years","70 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).",[27,28,29,30,31,32,33],"SLE (Systemic Lupus)","Lupus Erythematosus, Systemic","Lupus Nephritis","Systemic Sclerosis","Inflammatory Myopathy, Idiopathic","Myositis","Diffuse Cutaneous Systemic Sclerosis",[35,36,37,29,38,39,40,41,32,42,43,44,45,46,47],"CAR T","Lupus","SLE","Allogeneic","CD19","Cell Therapy","Scleroderma","Systemic sclerosis","Idiopathic Inflammatory Myopathy","Inflammatory Myopathy","Diffused Cutaneous Systemic Sclerosis","Gene Therapy","Autoimmune","RECRUITING","2026-06-11",{"date":51,"type":52},"2026-06-15","ACTUAL",{"date":54,"type":52},"2025-03-10",{"date":56,"type":21},"2031-12-31",{"name":58,"class":59},"CRISPR Therapeutics","INDUSTRY",14,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100563222","phase-1-a-study-of-cln-978-a-subcutaneously-administered-cd19-directed-t-cell-engager-in-subjects-with-systemic-lupus-erythematosus-100563222","NCT06613360","A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus","A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)","Inclusion Criteria:\n\n* Diagnosis of SLE at least 24 weeks prior to Screening and meet 2019 EULAR \u002F ACR Classification Criteria at screening.\n* Presence of one or more of the following autoantibodies documented during screening or in the previous 12 months before screening: positive anti-nuclear antibody (ANA) test (≥1:80); anti dsDNA above the upper limit of normal (ULN); anti-Sm above the ULN.\n* Active SLE disease, as demonstrated by a SLEDAI total score ≥6 at screening.\n* Inadequate response to at least 2 of the following treatments: oral corticosteroid, antimalarials, conventional immunosuppressants, or biologics. At least one of the failed treatments should be an immunosuppressive or biologic standard-of care agent.\n* If on corticosteroid and\u002For antimalarial, the dose must be stable prior to day 1.\n* Laboratory parameters including the following:\n\n  * Absolute lymphocyte count (ALC) ≥0.5 x 109\u002FL\n  * Peripheral B cell count ≥25 cells\u002FµL\n  * Absolute neutrophil count (ANC) ≥1.0 x 109\u002FL\n  * Hemoglobin ≥8 g\u002FdL\n  * Platelet count ≥75 x 109\u002FL.\n  * Estimated glomerular filtration rate (eGFR) (based on CKD-EPI formula) ≥30 mL\u002Fmin\u002F1.73m2\n  * Total bilirubin ≤1.5 × ULN, except patients with confirmed Gilbert's Syndrome\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN\n* Part B only: For patients who were treated in Part A and did not experience dose-limiting toxicity (DLT) or discontinue CLN-978 treatment due to AEs are eligible for retreatment at a higher dose or longer schedule in Part B if they otherwise meet eligibility criteria and at least 90 days have passed since the last dose of CLN-978.\n\nExclusion Criteria:\n\n* Active inflammatory disease other than SLE. Thyroiditis or secondary Sjogren's syndrome is allowed.\n* Considered at high risk for thrombosis.\n* Rapidly progressive glomerulonephritis, and\u002For urine protein\u002Fcreatinine \\>3 mg\u002Fmg (339 mg\u002Fmmol).\n* Active severe neuropsychiatric\u002FCNS manifestations of SLE.\n* Evidence of hepatitis B, hepatitis C (HCV) infection, human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) infection.\n* History of splenectomy.\n* Prior treatment with the following:\n\n  * Cellular or gene therapy product directed at any target.\n  * Investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to Day 1.\n  * Any anti-CD19 or anti-CD20 therapy less than 3 months prior to Day 1.\n  * Non-biologic DMARD within 14 days prior to Day 1.\n  * Cyclophosphamide within 1 month or a biologic immunomodulating therapy during 2 months prior to Day 1.\n* Live or attenuated vaccine within 28 days prior to screening or during screening.\n* Active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including SARS-CoV-2 infection, within 14 days before Day 1.\n* Active or latent tuberculosis (TB) evidenced by a positive or indeterminant Interferon Gamma Release Assay (IGRA), unless the patient has documented previous completion of TB treatment and no current clinical indication of TB.\n* Any condition for which, in the opinion of the Investigator and\u002For Sponsor, would not be in the best interest of the patient to participate in the study or that could prevent, limit, or confound any protocol-defined assessment.",{"count":69,"type":21},24,[24],"Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).",[37,27],[74],"Systemic Lupus Erythematosus","2026-06-04",{"date":77,"type":52},"2026-06-05",{"date":79,"type":52},"2025-01-21",{"date":81,"type":21},"2027-12",{"name":83,"class":59},"Cullinan Therapeutics Inc.",20,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100632665","phase-1-first-in-human-study-of-ish0613-safety-tolerability-pharmacokinetics-and-pharmacodynamics-100632665","NCT07516639","First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics","A Randomized, Double-Blind, Placebo-Controlled Phase Ia First-in-Human Study to Evaluate the Single Intravenous Administration of ISH0613 in Healthy Subjects","Inclusion Criteria:\n\n1. Healthy Chinese adult subjects, male or female, aged 18 to 45 years (inclusive);\n2. Body mass index (BMI) between 19.0 and 28.0 kg\u002Fm² (inclusive); body weight generally ≥50 kg for males and ≥45 kg for females;\n3. Male subjects and their partners, or female subjects, must agree to use at least one effective non-pharmacological contraceptive method (e.g., complete abstinence, intrauterine device, partner sterilization) during the study period, and must have no plan for sperm or egg donation;\n4. Subjects are able to fully understand the purpose, nature, and procedures of the study, including potential adverse reactions, and voluntarily sign the informed consent form (ICF);\n5. Subjects are able to communicate well with the investigator and are willing and able to comply with all study procedures and requirements.\n\nExclusion Criteria:\n\n1. Known allergy to the investigational product or any of its excipients, or a history of hypersensitivity to monoclonal antibodies;\n2. History or presence of clinically significant diseases of the cardiovascular, endocrine, nervous, gastrointestinal, respiratory, genitourinary, hematological, immunological, psychiatric, or metabolic systems, or any other condition that may interfere with study results, as judged by the investigator;\n3. Clinically significant abnormalities in laboratory tests (hematology, urinalysis, biochemistry, coagulation) or auxiliary examinations (chest X-ray, abdominal ultrasound);\n4. Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus (HIV) antibody, or syphilis antibody;\n5. Receipt of any surgical procedure within 6 months prior to signing the informed consent form, or planned surgery (including cosmetic, dental, or oral surgery) within 2 weeks after the end of the study;\n6. Alcohol consumption exceeding 14 units per week within 3 months prior to screening (1 unit = 360 mL beer, 150 mL wine, or 45 mL liquor), or positive alcohol breath test at screening or baseline, or inability to abstain from alcohol during the study;\n7. Average smoking of more than 5 cigarettes per day within 3 months prior to screening;\n8. History of drug abuse, use of soft drugs (e.g., cannabis) within 3 months prior to screening, or use of hard drugs (e.g., cocaine, phencyclidine) within 1 year prior to screening, or positive drug abuse screening test (including morphine, ketamine, THC-COOH, methamphetamine, MDMA, cocaine);\n9. Habitual excessive intake within 4 weeks prior to screening of caffeine-containing beverages or foods or substances that may affect drug metabolism, such as coffee (\\>1100 mL\u002Fday), tea (\\>2200 mL\u002Fday), cola (\\>2200 mL\u002Fday), energy drinks (\\>1100 mL\u002Fday), or chocolate (\\>510 g\u002Fday);\n10. Use of any prescription drugs, over-the-counter medications, or traditional Chinese medicines within 14 days prior to dosing;\n11. Receipt of any monoclonal antibody therapy within 6 months prior to dosing;\n12. Vaccination within 3 months prior to dosing, or planned vaccination during the study period;\n13. Participation in another clinical trial and receipt of investigational drug treatment within 3 months prior to dosing;\n14. Blood donation or significant blood loss (\\>400 mL, excluding menstrual loss) within 3 months prior to screening, or receipt of blood transfusion or blood products, or planned blood donation during the study period or within 1 month after study completion;\n15. Pregnant or lactating women;\n16. Clinically significant abnormal vital signs (systolic blood pressure \\\u003C90 mmHg or ≥140 mmHg; diastolic blood pressure \\\u003C55 mmHg or ≥90 mmHg; heart rate \\\u003C50 bpm or \\>100 bpm; body temperature \\\u003C35.4°C or \\>37.3°C), or clinically significant ECG abnormalities (QTcF \\>450 ms for males, \\>470 ms for females), or clinically significant findings on physical examination, as judged by the investigator;\n17. Presence of infection requiring treatment for acute or chronic infection, including but not limited to:\n\n    1. Herpes zoster within 12 months prior to screening;\n    2. Current suppressive therapy for chronic infections (e.g., tuberculosis, Pneumocystis, cytomegalovirus, herpes simplex virus, varicella-zoster virus, or atypical mycobacteria);\n    3. History of tuberculosis or contact with active tuberculosis within 6 months prior to screening, or positive T-SPOT test;\n    4. Parasitic infection within 3 months prior to dosing;\n    5. Hospitalization due to infectious disease within 30 days prior to dosing;\n    6. Parenteral anti-infective treatment (including antibacterial, antiviral, antifungal, or antiparasitic agents) within 30 days prior to dosing;\n18. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.",true,"45 Years",{"count":95,"type":21},26,[24],"The goal of this clinical trial is to learn about a study drug called ISH0613 and how it behaves in healthy adults.\n\nThis study will also evaluate the safety and tolerability of ISH0613 after a single intravenous (IV) dose.\n\nThe main questions this study aims to answer are:\n\nI. What medical problems (side effects) may occur after receiving ISH0613? How does ISH0613 move through and get processed in the body? II. Does ISH0613 affect certain biological markers related to the immune system? III. Researchers will compare ISH0613 to a placebo (a look-alike substance that contains no active drug) to better understand its effects.\n\nParticipants will:\n\nI. Receive a single intravenous infusion of either ISH0613 or placebo II. Stay in the clinical unit for several days for close monitoring after dosing III. Return to the clinic for follow-up visits over several weeks IV. Provide blood samples for safety checks and laboratory testing V. Be monitored for any side effects throughout the study",[99,27],"Healthy Subjects (HS)","NOT_YET_RECRUITING","2026-04-07",{"date":103,"type":52},"2026-04-13",{"date":105,"type":21},"2026-04-01",{"date":107,"type":21},"2026-12-31",{"name":109,"class":59},"SUNHO（China）BioPharmaceutical CO., Ltd.",1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100612999","phase-2-a-multicenter-randomized-double-blind-placebo-controlled-phase-2a-study-with-an-open-label-extension-evaluating-the-efficacy-and-safety-of-vent-03-in-adult-participants-with-active-cutaneous-lupus-erythematosus-with-or-without-systemic-lupus-erythematosus-100612999","NCT07260877","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus","AERIS","Key Inclusion Criteria:\n\n* Cutaneous lupus:\n\n  * CLASI-A score ≥8;\n  * At least 1 active discoid lupus erythematosus (DLE) lesion, OR at least 1 active subacute CLE lesion\n* If participant has previous SLE diagnosis:\n\n  * Positive antinuclear antibody test at Screening by immunofluorescent assay at the central laboratory with titer ≥ 1:80;\n  * Meets the American College of Rheumatology\u002F European Alliance of Associations for Rheumatology 2019 criteria for SLE; and\n  * Currently receiving at least one of the specified SLE medication treatments, at stable doses.\n\nKey Exclusion Criteria:\n\n* Meet protocol-specified infection or lab criteria; any other laboratory test results that, in the investigator's opinion, might place participant at unacceptable risk for participating in this study;\n* Moderate or severe liver impairment as classified by the Child-Pugh criteria (categories B and C);\n* Has drug-induced lupus, rather than 'idiopathic' lupus;\n* History of, or current, inflammatory joint or skin disease other than SLE and cutaneous lupus;\n* Diagnosis of select potentially confounding autoimmune disorders\n* Active severe or unstable neuropsychiatric SLE;\n* Hospitalization for a severe lupus flare in the past 3 months, or active severe SLE-driven disease, including lupus nephritis, for which in the opinion of the PI the protocol-specified SOC is insufficient;\n* History of or current diagnosis of anti-phospholipid syndrome;\n* History of any non-lupus disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to Day 1;\n* Meets protocol specified medical history of infectious diseases and infections and\u002For opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within specified timeframes;\n* Cancer screening results suspicious of malignancy or history of cancer within time specified with exceptions for curative therapy for squamous or basil cell carcinoma and cervical cancer in situ; and\n* Meets protocol specified exclusions related to concomitant medications.","80 Years",{"count":69,"type":21},[121],"PHASE2","The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are:\n\n* Does VENT-03 affect the activity and severity of CLE?\n* What side effects do participants have when taking VENT-03?\n\nResearchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE.\n\nParticipants will:\n\n* Take VENT-03 or a placebo for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks;\n* Visit the clinic once a month for checkups and tests.",[124,74,37,27,125],"Cutaneous Lupus Erythematosus (CLE)","CLE",[127,128],"CLE, SLE, lupus, cutaneous lupus erythematosus, systemic lupus erythematosus, VENT-03","cGAS","2026-03-30",{"date":131,"type":52},"2026-04-06",{"date":133,"type":52},"2025-12-03",{"date":135,"type":21},"2026-09",{"name":137,"class":59},"Ventus Therapeutics U.S., Inc.",27,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":110},"100558245","early-phase-1-clinical-study-on-targeted-cd19-or-cd19-bcma-car-t-therapy-for-autoimmune-diseases-100558245","NCT06548607","Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases","Inclusion Criteria:\n\n1. The subjects voluntarily participated in the study and signed the informed consent form.\n2. Age ≥18 years old and ≤70 years old, both sexes.\n3. Organ function and laboratory tests:\n\n   1. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN), total bilirubin (TBIL) ≤2×ULN (except Gilbert's syndrome).\n   2. Renal function: creatinine ≤1.5×ULN or creatinine clearance ≥40 ml\u002Fmin.\n   3. Blood routine: neutrophil count ≥1×10\\^9\u002FL, hemoglobin ≥60g\u002FL, platelet count ≥20×10\\^9\u002FL, lymphocyte count \\>0.3×10\\^9\u002FL.\n   4. Coagulation: international normalized ratio (INR) ≤ 1.5×ULN, or prothrombin time (PT) ≤ 1.5×ULN.\n   5. Oxygen saturation (SpO2) ≥92% at rest in room air.\n   6. Left ventricular ejection fraction (LVEF) ≥50% on echocardiography.\n4. Negative serum or urine pregnancy test results in female subjects of childbearing potential at screening.\n5. Women of childbearing potential must agree to use a highly effective method of contraception for at least 28 days before initiation of elution and up to 12 months after CAR-T reinfusion. Men of childbearing potential had to agree to the use of an effective barrier method of contraception from the initiation of lymphoidectomy until 12 months after reinfusion of CAR-T and had to refrain from donating semen or sperm throughout the trial.\n\nSLE Patient Inclusion Criteria:\n\n1. A definitive diagnosis of SLE according to the 2019 European League Against Rheumatism (EULAR) \u002F American College of Rheumatology (ACR) classification criteria or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria.\n2. Positive antinuclear antibodies (ANA) at screening, and\u002For positive anti-double-stranded DNA (anti-dsDNA) antibodies, and\u002For positive anti-Smith antibodies.\n3. A SLEDAI-2K score \\>6 at screening, and a 'clinical' SLEDAI-2K score ≥4.\n\nSSc Patient Inclusion Criteria:\n\n1. Diagnosed with SSc according to the 2013 ACR\u002FEULAR classification criteria.\n2. Diagnosed with diffuse cutaneous SSc at screening, with a disease duration ≤6 years.\n\nAAV Patient Inclusion Criteria:\n\n1. Meeting the diagnostic criteria for ANCA-associated vasculitis established by the 2022 ACR\u002FEULAR, including Microscopic Polyangiitis (MPA), Granulomatosis with Polyangiitis (GPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA).\n2. Positive testing for ANCA-associated antibodies 3 months before screening or at screening (specifically, positive anti-myeloperoxidase antibodies, MPO-ANCA, or positive anti-proteinase 3 antibodies, PR3-ANCA).\n\nIIM Patients Inclusion Criteria:\n\n1. Diagnosed with IIM according to the 2017 ACR\u002FEULAR classification criteria (including probable or definite diagnosis, i.e., probability ≥55%), including subtypes such as Dermatomyositis (DM), Anti-Synthetase Syndrome (ASS), and Immune-Mediated Necrotizing Myopathy (IMNM).\n2. Patients in the active phase, defined as those with at least 2 of the following six core set measures being abnormal: decreased muscle strength (MMT-8 \\\u003C142), Physician Global Assessment (PhGA, 10cm VAS) ≥2cm, Patient Global Assessment (PtGA, 10cm VAS) ≥2cm, Extramuscular Disease Activity Total Score (assessed using the MDAAT scoring tool) ≥2cm, Health Assessment Questionnaire (HAQ) ≥0.25, and Creatine Kinase (CK) muscle enzyme levels ≥1.5×ULN\n\nSjögren's Syndrome (SS) Patient Inclusion Criteria:\n\n1. Diagnosed with primary Sjögren's Syndrome according to the 2016 ACR\u002FEULAR classification criteria.\n2. Positive for anti-SSA\u002FRo antibodies detected 3 months before screening or at screening.\n3. A score of ≥5 on the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) at screening.\n\nExclusion Criteria:\n\n1. SLE Patients: Those with uncontrolled lupus crisis within the 8 weeks prior to screening, including rapidly progressive lupus nephritis, severe neuropsychiatric lupus, severe hemolytic anemia, severe immune thrombocytopenia, agranulocytosis, severe cardiac damage, severe lupus pneumonia, severe lupus hepatitis, and severe vasculitis, as assessed by the investigator as unsuitable to participate in this study.\n2. IIM Patients: Presence of severe rhabdomyolysis or CK levels ≥120×ULN at screening.\n3. Patients with severe asthma or Chronic Obstructive Pulmonary Disease (COPD) are eligible. Patients with mild or moderate asthma or COPD who are receiving stable treatment can also be enrolled.\n4. There has been an active infection requiring systemic treatment within 2 weeks prior to the urethral irrigation, such as infectious pneumonia, tuberculosis, etc.\n5. Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA in peripheral blood; positive for hepatitis C virus (HCV) antibody with detectable HCV RNA in peripheral blood; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis antibody.\n6. Pregnant or breastfeeding women.\n7. Any condition that, in the investigator's opinion, may affect study participation, pose a safety risk to the patient, or potentially confound the interpretation of study results.",{"count":84,"type":21},[147],"EARLY_PHASE1","This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CD19 or CD19-BCMA CAR-T in patients with active SLE, SSc, AAV, IIM and pSS.",[27,30,150,151,152,153],"ANCA Associated Vasculitis","Idiopathic Inflammatory Myopathies","Sjogren's Syndrome","Autoimmune Diseases","2026-03-04",{"date":156,"type":52},"2026-03-06",{"date":158,"type":52},"2024-09-14",{"date":160,"type":21},"2027-12-31",{"name":162,"class":59},"Nanjing Bioheng Biotech Co., Ltd.",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":171,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100620959","phase-1-efficacy-and-safety-of-crc01-in-participants-with-severe-refractory-systemic-lupus-erythematosus-100620959","NCT07364396","Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus","An Open-label, Multi-center, Single-arm Phase 1\u002F2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus","CRC01-02","Inclusion Criteria:\n\n* Age 19 years or older, voluntarily provides written informed consent.\n* Diagnosis of systemic lupus erythematosus (SLE) according to the 2019 EULAR\u002FACR classification criteria.\n* Positive antinuclear antibody (ANA) at screening (titer ≥1:80).\n* Diagnosis of lupus nephritis Class III or IV (with or without concurrent Class V), confirmed by kidney biopsy within 1 year prior to screening based on ISN\u002FRPS 2018 criteria.\n* Inadequate response to, or intolerance of, at least two or more standard therapies for 6 months or longer (cyclophosphamide, mycophenolate mofetil, azathioprine, tacrolimus, rituximab, belimumab).\n* Proteinuria at screening with urine protein-to-creatinine ratio (UPCR) \\>1.5.\n* Adequate laboratory values at screening: Hemoglobin \\>8.0 g\u002FdL; ANC \\>1,000\u002FμL; Platelets ≥50,000\u002FμL; Total bilirubin ≤2.0 × ULN; AST and ALT ≤3 × ULN; eGFR ≥30 mL\u002Fmin\u002F1.73 m².\n* Hemodynamically stable, no pericardial effusion, and LVEF ≥50% by echocardiogram at screening.\n* FEV1\u002FFVC ≥70% at screening.\n* Willing and able to comply with study visits, procedures, and requirements.\n* Women of childbearing potential and men must agree to use effective contraception for at least 1 year after CRC01 infusion until PCR testing confirms clearance of CRC01.\n\nExclusion Criteria:\n\n* Current or anticipated requirement for renal dialysis during the study.\n* History of kidney transplantation or planned transplantation during the study.\n* History of severe CNS lupus or currently active severe CNS lupus.\n* Prior CAR-T cell therapy.\n* History of malignancy except for: basal or squamous cell carcinoma of skin treated and disease-free ≥3 years; in-situ carcinoma of cervix or breast treated and disease-free ≥3 years; superficial bladder cancer treated and disease-free ≥3 years; completely resected primary malignancy in complete remission ≥5 years.\n* Unstable angina and\u002For myocardial infarction within 1 year prior to screening.\n* Congestive heart failure of NYHA Class III or IV within 1 year prior to screening.\n* Thromboembolism, pulmonary embolism, or clinically significant bleeding diathesis within 6 months prior to screening.\n* Hypoxemia, clinically significant pleural effusion, or abnormal ECG findings within 6 months prior to screening.\n* Stroke (ischemic or hemorrhagic) within 6 months prior to screening.\n* Positive HBsAg; positive anti-HCV (eligible if HCV RNA negative); known HIV infection; or active neurological autoimmune\u002Finflammatory diseases (e.g., Guillain-Barré syndrome, ALS).\n* Recurrent or symptomatic ventricular tachycardia, or atrial fibrillation with rapid ventricular response despite therapy within 3 months prior to screening.\n* Severe or uncontrolled active infection requiring systemic therapy at screening.\n* Rapidly progressive disease or otherwise unsuitable for study participation, per investigator judgment.\n* Pregnant or breastfeeding women.\n* Known hypersensitivity to investigational product components.\n* Participation in another investigational study within 4 weeks prior to screening.\n* Receipt of systemic corticosteroids at therapeutic doses within 7 days prior to leukapheresis (≤7.5 mg\u002Fday prednisone equivalent is permitted).\n* Receipt of immunosuppressive agents within 7 days prior to leukapheresis.\n* Receipt of antibody-based therapies (e.g., belimumab, rituximab, anifrolumab) within 4 weeks prior to leukapheresis.\n\nInclusion Criteria for CRC01 Infusion:\n\n* No clinically significant worsening of organ function after screening.\n* If any of the following adverse events related to lymphodepleting chemotherapy exceed Grade 1 or worsen compared with screening, CRC01 infusion must be delayed:\n\n  * Requirement for supplemental oxygen\n  * New arrhythmia symptoms or clinically significant changes in cardiac function compared with screening\n  * Hypotension requiring treatment\n  * Active infection within 72 hours prior to the planned CRC01 infusion\n\n    * If bacterial, viral, or fungal infection is documented, improvement of symptoms must be documented before infusion.\n* Women of childbearing potential must have a negative urine pregnancy test prior to infusion.\n* If CRC01 infusion is delayed for more than 2 weeks after lymphodepleting chemotherapy, administration may proceed only with approval from the sponsor's medical monitor.\n* No receipt of therapeutic doses of systemic corticosteroids or immunosuppressive agents within 7 days prior to CRC01 infusion. (Prednisone ≤7.5 mg\u002Fday or equivalent is permitted.)\n* No receipt of antibody-based therapies (e.g., belimumab, rituximab, anifrolumab) within 4 weeks prior to CRC01 infusion.","19 Years",{"count":173,"type":21},39,[24,121],"The purpose of this clinical trial is to evaluate the safety and efficacy of CRC01, an investigational autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, in people with lupus nephritis (LN), a serious kidney complication of systemic lupus erythematosus (SLE).\n\nThe main objectives of the study are:\n\n1. To determine whether CRC01 infusion can improve kidney outcomes and reduce disease activity in participants with lupus nephritis.\n2. To assess the safety profile, including potential risks such as cytokine release syndrome (CRS) and neurotoxicity.\n\nStudy Design This is a single-arm, open-label, multi-center, Phase 1\u002F2 study. All enrolled participants will receive CRC01 after screening and baseline assessments.\n\nStudy Procedures\n\nParticipants will:\n\n* Undergo eligibility screening, including blood tests, urine tests, and disease activity assessments.\n* Provide autologous T lymphocytes through a procedure called leukapheresis.\n* Receive a lymphodepleting pre-conditioning regimen (short course of chemotherapy).\n* Receive a single intravenous infusion of CRC01 cells.\n* Be hospitalized for close monitoring to detect and manage early adverse events such as CRS or neurotoxicity.\n* Return for scheduled follow-up assessments through Week 52 (12 months) post-infusion to evaluate safety and treatment response.\n\nKey Outcomes\n\nResearchers will measure:\n\n* Changes in proteinuria and kidney function.\n* Changes in disease activity scores.\n* Incidence and severity of adverse events.",[29,177,37,27],"Lupus Nephritis (LN)","2026-01-21",{"date":180,"type":52},"2026-01-23",{"date":182,"type":21},"2026-02",{"date":184,"type":21},"2030-06",{"name":186,"class":59},"Curocell Inc.",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":110},"100590783","phase-2-efficacy-and-safety-of-low-dose-il-2-in-sle-patients-with-cmv-viremia-100590783","NCT06971913","Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia","Inclusion Criteria:\n\n* Meet the American College of Rheumatology criteria for the diagnosis of SLE.\n* The test for plasma CMV DNA viral load is positive.\n* Age: 18 to 65 years, weight 45-80kg, male or female, gender ratio is not limited.\n* Apply corticosteroid less than 1.0mg\u002Fkg\u002Fd.\n* Written informed consent form.\n\nExclusion Criteria:\n\n* Inability to comply with IL-2 treatment regimen;\n* Other active infections. (hepatitis B or C virus, Epstein-Barr virus, human immunodeficiency virus, Mycobacterium tuberculosis or pneumocystis carinii pneumonia)\n* Any anti-CMV vaccine within 6 months;\n* History of intravenous immunoglobulin (IVIG) or leflunomide within 6 months prior to randomization, and those who have undergone plasmapheresis;\n* Active severe neuropsychiatric manifestations of SLE;\n* Severe chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III NYHA), hepatic insufficiency (transaminases\\> 3N));\n* Severe complications. (respiratory failure, heart failure or toxic shock)\n* Complicated with other autoimmune diseases;\n* Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma);\n* Pregnancy or lactation in females.\n* Mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information;\n* Participate in other clinical trial within 3 months.","65 Years",{"count":195,"type":21},100,[121],"This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.",[27,199],"CMV","2025-05-07",{"date":202,"type":52},"2025-05-14",{"date":204,"type":21},"2025-05-20",{"date":206,"type":21},"2025-12-30",{"name":208,"class":209},"Peking University People's Hospital","OTHER",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":110},"100562995","assessment-of-cxcl5-level-in-sle-patients-and-its-correlation-with-disease-activity-100562995","NCT06610409","Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity","Inclusion Criteria:\n\n* Age \\>18 years old\n* Patients who are diagnosed as SLE according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) Citeria (10,11).\n\nExclusion Criteria:\n\n* age \\\u003C 18 years old\n\n  * Patients unwilling to participate in the study.\n  * Patients with other autoimmune diseases.\n  * Patients with malignancy or infections.\n  * Pregnancy and lactation",{"count":217,"type":21},90,"OBSERVATIONAL","Assessment of CXCL5 biomarker in Serum of patients of SLE in comparison to healthy patients and its correlation with disease activity",[27],"2024-09-20",{"date":223,"type":52},"2024-09-24",{"date":225,"type":21},"2024-10-01",{"date":227,"type":21},"2027-09-30",{"name":229,"class":209},"Assiut University",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":110},"100520465","phase-1-safety-and-efficacy-of-cd19-targeted-car-t-therapy-for-refractory-autoimmune-disease-100520465","NCT06056921","Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease","Clinical Study of CD19 Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Refractory Autoimmune Diseases","Inclusion Criteria:\n\n1. ≥18 years old, male or female;\n2. diagnosed with one of the following diseases:\n\n   * Systemic Lupus Erythematosus (SLE), EULAR\u002FACR 2019 standard;\n   * Sjogren's Syndrome (SS), 2016 ACR\u002FEULAR standard;\n   * Systemic Scleroderma (SSc), 2013 ACR\u002FEULAR Standards;\n   * Dermatomyositis (DM), 2017 EULAR\u002FACR classification standard + one positive myositis specific antibody (Jo-1, Zo, EJ, PL-7, KS, OJ, PL-12, YRS, Anti-NXP-2, Anti-TIF1g, Anti-Mi-2, Anti-SAE, Anti-MDA-5, Anti-SRP, Anti-HMGCR);\n   * Anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-AAV), including granulomatosis with polyangiitis (GPA), or microscopic vasculitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA), 2022 ACR\u002FEULAR standard.\n3. Disease activity meets the following requirements:\n\n   * SLEDAI score ≥8 for SLE patients;\n   * For SS patients, ESSDAI≥14 points;\n   * For patients with SSc, mRSS score in the range of 10-35 (including the boundary value) with interstitial pneumonia (ILD);\n   * Patients with DM who have been diagnosed for at least 1 year and meet the following conditions:\n\n     1\\. Skin rash VAS score (based on MDAAT) ≥3cm with at least 3 abnormalities in CSM;\n\n     2, muscle biopsy pathology or muscle nuclear magnetic evidence of active inflammation;\n\n     3\\. Bilateral manual muscle strength test (MMT-8) is less than 125\u002F150, and at least 2 additional Core set measures (CSM) meet the following criteria: Patient score, 10 cm visual analogue scale (VAS) no less than 2.0 cm; b. Physician score, no less than 2.0 cm on the 10 cm VAS scale; c. Health Assessment Questionnaire (HAQ) disability index (Appendix 10) of not less than 0.25; d. Elevation of at least one muscular enzyme (including creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), with a minimum level of 1.3× the upper limit of normal; e. Disease activity score of extramuscular organs, no less than 1.0 cm on the 10 cm VAS scale (this VAS is the physician's comprehensive assessment of myositis disease Activity Assessment Tool (MDAAT) based on the general condition, skin, bone, gastrointestinal, lung, and heart scale activity score);\n   * For ANCA-AAV patients, the BVAS score was ≥15.\n4. ECOG 0\\~1 score;\n5. The functions of important organs are basically normal:\n\n   * Hematology: hemoglobin ≥60g\u002FL, platelet count ≥30×109\u002FL;\n   * Cardiac function: Left ventricular ejection fraction (LVEF) ≥55%, no obvious abnormality in electrocardiogram;\n   * Renal function: eGFR≥30ML\u002Fmin\u002F1.73m2;\n   * Liver function: AST and ALT≤3.0 ULN, total bilirubin ≤2.0 ULN;\n   * Lung function: DLCO≥40% predicted value; FVC≥50% expected value;\n   * Have criteria for simple or intravenous blood collection, and no other contraindications for cell collection;\n6. The subject of childbearing age has a negative urine pregnancy test result and agrees to take effective contraceptive measures during the test period until 1 year after the infusion;\n7. The patient or his\u002Fher guardian agrees to participate in the clinical trial and signs the informed consent, indicating that he\u002Fshe understands the purpose and procedure of the clinical trial and is willing to participate in the study.\n\nExclusion Criteria:\n\n1. Had previously received CAR T cell therapy;\n2. patients with serious heart, liver, lung, blood system, endocrine system diseases, and the risk of participating in the trial is higher than the benefit judged by the researcher;\n3. There is an active or uncontrollable infection that requires systemic treatment within 1 week prior to screening;\n4. have previously received hematopoietic stem cell transplantation or solid organ transplantation (except corneal and hair transplantation), or have grade 2 or higher acute graft-versus-host disease (GVHD) within 2 weeks prior to screening;\n5. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for human immunodeficiency virus (HIV) antibodies; Or syphilis test positive; Or cytomegalovirus (CMV) DNA test positive;\n6. Had received live vaccine within 4 weeks before screening;\n7. pregnancy test positive;\n8. Patients with malignant diseases such as malignant tumors before screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery;\n9. Patients who had participated in other clinical trials within 3 months prior to screening;\n10. Situations in which other investigators consider it inappropriate to participate in the study.",{"count":69,"type":21},[24],"This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease",[27,152,241,242,243],"Systemic Scleroderma","Dermatomyositis","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",[245,39],"CAR-T","2023-09-25",{"date":248,"type":52},"2023-09-28",{"date":250,"type":52},"2023-08-31",{"date":252,"type":21},"2026-08-31",{"name":254,"class":59},"Chongqing Precision Biotech Co., Ltd",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":171,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":110},"100408939","national-systemic-lupus-erythematosus-prospective-cohort-saudi-arabia-100408939","NCT04604990","National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia","Inclusion Criteria:\n\n1. Adult patients defined as age greater than 18 years old.\n2. Patients should fulfil one of the following classification criteria for SLE (ACR, SLICC or ACR\u002FEULAR criteria).\n3. No restriction on time of diagnosis.\n\nExclusion Criteria:\n\n* Patients who don't fulfil classification criteria mentioned above.",{"count":262,"type":21},1000,"SLE disease in Saudi Arabia is yet not well defined especially in a population with high consanguinity and high inbreeding coefficient . Up until now, there has been no prospective cohort study for SLE patients in Saudi Arabia. As a result, current published literature is focused on retrospective chart reviews which are subjected to many forms of bias. so the investigator proposed this prospective registry which will follow open cohort study design aiming to provide better understanding of disease presentation, course and outcomes especially if complemented by detailed immunological, molecular, genetic and microbiome data.",[27],[37,266,267,268,269],"Lupus erythematosus","Outcomes","Phenotypes","Observational","2021-08-31",{"date":272,"type":52},"2021-09-01",{"date":274,"type":52},"2020-12-20",{"date":276,"type":21},"2050-11-01",{"name":278,"class":209},"King Saud University"]